Royal Melbourne Hospital set to host preliminary trial for a new stem cell therapy

By Uwear

In an attempt to discover a cure Parkinson’s disease and other brain degeneration diseases, U.S.-based International Stem Cell Corporation (ISCO) will have a world-first trial for an innovative stem cell therapy at Royal Melbourne Hospital.

The trial will be run by ISCO’s Aussie subsidiary, Cyto Therapeutics, and will consist of 12 Parkinson’s patients who will be injected with neural stem cells before being observed for one year. Doctors will monitor the subjects to see if they are able to boost the brain’s capacity to produce and release the chemical messenger dopamine, which is lost in Parkinson’s patients.

RELATED TOPIC: TransMedics creates new Organ Care System being used in Australia

“Dopamine is one of the most critical neurotransmitters or chemical messengers in the brain, and the loss of this neurotransmitter is directly linked to the development of the cardinal features that include stiffness, slowness and shaking,” said Melbourne neurologist Dr. Andrew Evans.

“It’s hoped that through replenishment of the dopamine through these neural stem cells, which show some capacity to differentiate into obviously dopamine producing cells in the annual models, we are hoping to restore some of the functions in patients with Parkinson’s disease.”

RELATED TOPIC: Google Australia supports Aussie children, invests in STEM

Australia was chosen to host the initial phase one of the trial due to its high standard in clinical research as well as its culture of innovation. If the first phase is deemed successful, larger trials in Australia, the U.S. and Europe will commence within the next couple years.

With Japan establishing itself as the global hub of stem cell technology, stem-cell based regenerative medicines can be made available in Japan only if it makes it past phase-two trials. So unlike other countries, this will require a third round of clinical testing.

RELATED TOPIC: Will Australia change cranial reconstruction with new 3D printing technology?

Parkinson’s disease affects nearly 10,000 people across the globe, including 80,000 Australians, with symptoms including movement restrictions, shaking, dementia and other behavioural problems. According to ISCO chief scientific officer Dr. Russell Kern, a single injection of the stem cells could generate a lifetime supply of neurons.

Successful preliminary and subsequent trials would be a revolutionary breakthrough for using stem cells to treat other diseases that cause brain degeneration, including ALS or Lou Gehrig’s disease.

RELATED TOPIC: 4WEB Medical brings 3D printing implants to Australia

Because so many Aussie companies are creating new ways of extracting stem cells from human tissues such as flood and fat, the federal government views stem cell technology as a way to stimulate the nation’s economy.

Let's connect!  

Check out the latest edition of Business Review Australia!




Featured Articles

Nirvik Singh, COO Grey Group on adding colour to campaigns

Nirvik Singh, Global COO and President International of Grey Group, cultivating culture and utilising AI to enhance rather than replace human creativity

How Longi became the world’s leading solar tech manufacturer

On a mission to accelerate the adoption of sustainable energy solutions, US$30 billion Chinese tech firm Longi is not just selling solar – but using it

How Samsung’s US$5billion sustainability plan is working out

Armed with an ambitious billion-dollar strategy, Samsung is on track to achieve net zero carbon emissions company-wide by 2050 – but challenges persist

UOB: making strides in sustainability across Southeast Asia


Huawei smartwatch goes for gold with Ultimate Edition


How IKEA India plans to double business, triple headcount

Corporate Finance